Recent developments include executive appointments, significant revenue growth announcements, and operational milestones in robotic telesurgery.

• SS Innovations appointed veteran medtech finance executive Sarah Romano as CFO effective August 3, 2026, with a three-year employment agreement and stock option grants [N1].
• The company posted preliminary full-year 2025 revenue growth of 108% as announced in January 2026 [N3].
• SS Innovations announced preliminary unaudited revenue for Q4 and full year 2025 in January 2026 [N4].
• The company achieved milestones including the first intercontinental robotic cardiac telesurgery using the SSi Mantra 3 system and over 100 installations of its surgical robotic system worldwide [N2].

The company has shown rapid revenue growth and operational milestones in a specialized and emerging field of surgical robotics. Its ability to complete pioneering robotic surgeries and expand installations globally indicates potential for continued adoption of its technology. Recent executive appointments with experienced medtech finance professionals may support strategic growth and operational execution.

Despite revenue growth, the company reported a net loss in the latest quarter, indicating ongoing profitability challenges. The surgical robotics market is competitive and capital intensive, with risks related to technology adoption, regulatory approvals, and execution. Changes in key financial leadership may also introduce transitional risks. The company is classified as a smaller reporting company, which may limit the scope of disclosed risk factors and financial detail.

SS Innovations' moat is based on its pioneering technology in surgical robotics, demonstrated by its early achievements in intercontinental and remote robotic telesurgery. The company's installations of over 100 robotic systems worldwide and recognition in the surgical robotics industry suggest a competitive position supported by technological innovation and operational milestones. However, detailed information on intellectual property, competitive landscape, or barriers to entry is not explicitly disclosed in the available filings.

• Profitability Risk: The company reported a net loss of $2.66 million for Q2 2026, indicating challenges in achieving profitability despite revenue growth.
• Market and Competitive Risk: Operating in the surgical robotics sector involves competition and the need for continuous innovation and regulatory compliance, which may impact business performance.
• Executive Transition Risk: Recent changes in the CFO position may affect financial management and strategic execution during the transition period.

• SS Innovations International, Inc. is a company incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
• The company is listed on The Nasdaq Stock Market under the ticker SSII.
• As of March 9, 2026, the company had 200,231,535 shares outstanding and a market value of voting and non-voting common equity held by non-affiliates of approximately $270 million.
• The company operates in the medical technology sector, specifically in surgical robotics, as evidenced by multiple news reports on robotic telesurgery milestones and product installations.
• SS Innovations has achieved milestones including over 100 installations of its SSi Mantra surgical robotic system worldwide and first intercontinental robotic cardiac telesurgery using the SSi Mantra 3 system.
• The company completed the world's first remote robotic telesurgery for weight loss and the first robotic cardiac surgery in the Americas using its system.
• SS Innovations was named the winner of the Outstanding Company category at the 2026 Surgical Robotics Industry Awards.
• The company has experienced significant revenue growth, with preliminary full-year 2025 revenue growth of 108% and Q2 2025 revenue up 122%.
• Financial figures from the latest SEC 10-Q filing for the quarter ended June 30, 2026, include cash and equivalents of $13.65 million, current assets of $71.45 million, current liabilities of $31.89 million, resulting in a current ratio of 2.24 and a cash ratio of 0.43.
• Revenue for Q1 2026 was $11.1 million, and net income for Q2 2026 was a loss of $2.66 million, with basic and diluted EPS of -$0.01 per share.
• The company has undergone CFO changes recently, appointing Sarah Romano as CFO effective August 3, 2026, following a prior appointment of Naveen Kumar Amar in September 2025.
• The company files as a smaller reporting company and is not required to provide certain risk factor disclosures.
• The company has a history of press releases and SEC filings that provide transparency on financial results, executive appointments, and business milestones.